I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation
about
Heterogeneous nuclear ribonucleoprotein P2 is an autoantibody target in mice deficient for Mer, Axl, and Tyro3 receptor tyrosine kinasesComplement classical pathway components are all important in clearance of apoptotic and secondary necrotic cellsAnnexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cellsRole of Natural Autoantibodies and Natural IgM Anti-Leucocyte Autoantibodies in Health and DiseaseHere, There, and Everywhere: The Ubiquitous Distribution of the Immunosignaling Molecule Lysophosphatidylcholine and Its Role on Chagas DiseaseSLE-associated risk factors affect DC functionPhospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interventionNatural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune diseaseCharacterization of the human patatin-like phospholipase familyThe role of phospholipases A2 in schizophreniaDo not let death do us part: 'find-me' signals in communication between dying cells and the phagocytes.Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestionSequence-specific binding of normal serum immunoglobulin M to exposed protein C-termini.The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus.Group VIA Ca2+-independent phospholipase A2 (iPLA2beta) and its role in beta-cell programmed cell death.Inhibitory effect of platinum and ruthenium bipyridyl complexes on porcine pancreatic phospholipase A2.Review: Soluble innate immune pattern-recognition proteins for clearing dying cells and cellular components: implications on exacerbating or resolving inflammation.Sca-1 influences the innate immune response during skeletal muscle regeneration.Phagocytosis of opsonized apoptotic cells: roles for 'old-fashioned' receptors for antibody and complement.Evaluation of the contribution of multiple DAMPs and DAMP receptors in cell death-induced sterile inflammatory responses.Lysophosphatidylcholine: A Novel Modulator of Trypanosoma cruzi TransmissionIgM colocalises with complement and C reactive protein in infarcted human myocardium.IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells.Development and selection of marginal zone B cells.Circulating IgM Requires Plasma Membrane Disruption to Bind Apoptotic and Non-Apoptotic Nucleated Cells and Erythrocytes.Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice.Autoreactivity in human IgG+ memory B cells.Manipulation of the glycan-specific natural antibody repertoire for immunotherapyActivated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals.FcγRIIb and BAFF differentially regulate peritoneal B1 cell survival.Calcium-independent phospholipases A2 and their roles in biological processes and diseases.IgM exacerbates glomerular disease progression in complement-induced glomerulopathyBLyS antagonists and peptide tolerance induction.Major Alterations of Phosphatidylcholine and Lysophosphotidylcholine Lipids in the Substantia Nigra Using an Early Stage Model of Parkinson's Disease.SLE, atherosclerosis and cardiovascular disease.Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus.Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatoryDefective B cell tolerance checkpoints in systemic lupus erythematosusThe role of CR2 in autoimmunity.Complement deficiencies in humans and animals: links to autoimmunity.
P2860
Q24299348-3C62078E-DEA7-480B-BEB3-F0CF61D48FADQ24322831-1D75CAE2-6C46-4CD6-B819-70A579E40CC7Q24646683-C4F6DC49-BE4A-4D87-A0D8-AAC32023D49CQ26745015-85CBA728-5796-4660-8512-599721618FB5Q26765838-04B126D2-D4BA-4DBF-95EC-A24EC3CDFDE0Q26774797-5D698B52-A670-4A24-96BD-8A6E71581A14Q26997377-9A1AB479-2C7E-43DD-AAAE-7E0819F5D3A7Q27021242-3262263C-A3B2-4869-874E-C6D349EC8BC2Q28248355-58C95C88-D07C-4BD3-BEC6-8A06D2724827Q28305324-05FEFA95-5994-405A-AC92-6F21A28E26E5Q30277318-AD24EA84-C098-4780-B62E-A2D5F8EACAB3Q30408786-79F555DD-9636-43E9-8DE3-590706EB725AQ31061968-42EDAE27-506A-463E-9B22-524405CAB4D8Q33754111-2358BDB2-C8D0-4F27-8FCC-1EFDB6F11798Q33886495-75CD7D7B-79C3-451A-BB90-09D8E1395B61Q34016733-1C81FB00-4D6D-4580-B40D-967DA180F008Q34119510-FED336C0-2A89-4D7B-A707-1DFB1D8AF3D8Q34597576-3A3CE284-6687-4C26-B2DF-1A8DC3D40802Q34649313-E0C8F832-3C76-4A5E-9DDB-2C5E7E1A6B93Q35225843-472CBD78-D4FF-44F8-AFA5-1B87175F1208Q35503605-47E22059-F9A4-47DE-B35F-84618F26D902Q35588500-A876D6A1-9DB8-4519-93A1-90B7783A759FQ35597401-3617C59F-168F-4737-B5C9-102AD2A48C5DQ35666707-1C0BC7B1-89C6-4A60-9261-2D4530BC3F69Q35677438-2E33C935-5DE3-424B-A731-D21121F9DD5EQ35685695-E37D8D25-8918-4428-9BB0-BD519D78DBC6Q35729131-22C6CAD6-4B88-4227-B791-FB9E4B99278AQ35920081-852B9DEB-33B5-4B02-B377-5D43C55A0049Q35953495-75701D45-65B1-46E8-9216-FB813E51E474Q35991862-5277A846-7BAB-4B16-82E4-8D921B5533F7Q35994344-B649BFB0-3E1C-4002-B953-2C45116551F7Q36016859-149A82FD-E0F7-4FC5-89E6-255C5163491FQ36088054-DA6114C4-ADC6-4102-A85B-94453D55F3EDQ36088639-0DBE6E58-0286-4C47-A3DA-E0DF344A3F4EQ36135534-FD7ED458-459A-4A02-8A13-F6B5D790B042Q36215324-228814EA-B3FE-44D2-9492-6CDD6663CA56Q36399652-DAFAA2F1-F989-4633-81C9-6119DA5CAC70Q36402748-68D40C23-AC13-4602-A4EF-2E844ED8B1EDQ36572973-808B48DD-7011-41DB-9EB0-A24C1CAF00A2Q36572977-18F0E0EB-DE99-40E2-A185-6EE282ECFC18
P2860
I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
I-PLA(2) activation during apo ...... dies and complement activation
@ast
I-PLA(2) activation during apo ...... dies and complement activation
@en
I-PLA(2) activation during apo ...... dies and complement activation
@nl
type
label
I-PLA(2) activation during apo ...... dies and complement activation
@ast
I-PLA(2) activation during apo ...... dies and complement activation
@en
I-PLA(2) activation during apo ...... dies and complement activation
@nl
prefLabel
I-PLA(2) activation during apo ...... dies and complement activation
@ast
I-PLA(2) activation during apo ...... dies and complement activation
@en
I-PLA(2) activation during apo ...... dies and complement activation
@nl
P2093
P2860
P3181
P356
P1476
I-PLA(2) activation during apo ...... dies and complement activation
@en
P2093
Debra Gershov
Keith B Elkon
Nathan Brot
Sun Jun Kim
Xiaojing Ma
P2860
P304
P3181
P356
10.1084/JEM.20020542
P407
P577
2002-09-02T00:00:00Z